Search

A simple, selective, sensitive, accurate and relatively inexpensive method for the determination of palladium in bulk pharmaceutical chemicals (BPC) and their synthetic intermediates by graphite furnace atomic absorption spectroscopy has been developed and validated. Sample preparation by direct dissolution of sample in 70% nitric acid is simple and effective without adverse effects. The limit of detection and the limit of quantitation of the method were determined to be 0.7 ppm and 2 ppm respectively in BPC.

The existence of an isomeric form in equilibrium with the major component of FK-520 in polar solutions has been demonstrated. This minor component has been isolated in high yield and purity by a novel crystallization strategy and preparative HPLC. The equilibrium product was characterized by NMR and MS.

A multi-element inductively coupled plasma-mass spectrometry (ICP-MS) survey method has been demonstrated as an alternative to the antiquated 'heavy metals limit test' prescribed by United States Pharmacopoeia (USP), European Pharmacopoeia (EP), and British Pharmacopoeia (BP), for drug substances, intermediates, and raw materials. The survey method is simple, fast, sensitive, semi-quantitative to quantitative, and includes all the elements which can be analyzed by atomic spectroscopy.

The preparation of 4-de-N-methylfortimicin A analogs as well as the preparation of 4-de-N-methyl-4-N-(beta-aminoethyl)-4-N-ethylfortimicin B is reported. It was shown that the 4-N-methyl group in fortimicin analogs is essential for antibacterial activity since neither the 4-de-N-methylfortimicin A nor the 4-de-N-methyl-4-N-(beta-aminoethyl)-4-N-ethylfortimicin B exhibited useful biological activity.

Erythromycin A is slowly metabolized to a new antibiotic, erythromycin E (5), when incubated with fermentations of certain strains of the producing organism Streptomyces erythreus. Erythromycin E contains a novel ortho ester grouping not previously encountered in macrolide antibiotics. The isolation of erythromycin E extends and further delineates the latter stages of the erythromycin biogenetic pathway.

A further examination of the products from fermentation broths of Streptomyces violaceoniger has yielded small quantities of several lankamycin related antibiotics and metabolites. One of the antibiotics has been characterized as 3″-de-O-methyl-2″,3″-anhydro-lankamycin. The anhydro sugar of the new lankamycin, 3-methyl-4-O-acetyl-2,3,6-trideoxy-α-L-threo-hex-2-enepyranoside was also isolated as the ethyl glycoside from fermentation broths of the same organism.

7-Deoxy-4(R)-dihydrospectinomycin (7) has been prepared and its structure firmly established by proton magnetic resonance and high resolution mass spectrometry. This spectinomycin analog is devoid of antibiotic activity.

3-O-(2″,6″-Dideoxy-α- l -ribo-hexopyranosyl)erythronolide B (6) and 3-O-(2″,6″-dideoxy-α- l -arabino-hexopyranosyl)erythronolide B (7), aberrant metabolites of erythromycin biosynthesis, have been isolated from the fermentation broth of a blocked mutant of the erythromycin producing organism Streptomyces erythreus. The defective glycosidesm, when incubated with early blocked mutants of S. erythreus capable of converting authentic erythromycin progenitors to the complete antibiotic, were unmetabolized. The probable origin of the metabolite is discussed.

The structures of fortimicins A and B have been determined by PMR, CMR, mass spectra and CD combined with chemical degradations. Both antibiotics are pseudodisaccha-rides and incorporate a novel aminocyclitol, fortamine. Incontrast to the diaminocyclitol moieties of known aminoglycosides, fortamine is a 1, 4-diamine, contains both N- and O-methyl groups and possesses chiro stereochemistry. Both antibiotics are glycosides of 6-epi-pur-purosamine B, but fort imicin A differs from fortimicin B by being a glycyl amide.

The isolation and structure elucidation of a shunt metabolite of erythromycin biosynthesis, (8S)-8-hydroxy-5,6-dideoxy-5-oxoerythronolide B ( 1a ), is described. NMR and CD data reveal that the title compound and related 5-oxo derivatives ( 5 and 6 ) are conformationally homogeneous with erythronolide B ( 2 ). Consistent with this observation is the hydroxyketone-hemiacetal equilibrium present in the case of 5 . The spectroscopic data further show that 1a , (8S)8)hydroxyerythronolide B ( 12 ), and lankolide ( 13 ) have identical 8S stereochemistry.

8- epi -erythronolide B ( 4 ) has been isolated as a product formed from the acid treatment of erythronolide B ( 3 ). When this compound was fed to a blocked mutant of the erythromycin producing organism, Streptomycetes erythreus (Abbott 2NU153), nearly quantitative yields of 3- O -(α- l -mycarosyl)-8- epi -erythronolide B ( 10 ) were obtained. The much desired 8- epi -erythromycins ( 2 ) were not realized.

We have shown previously that the esters of adenosine-5'-carboxylic acid (10) represent a new class of potent nontoxic coronary vasodilators. For example, the ethyl ester (12), which is active by an intraduodenal or intravenous route in dogs, causes a large increase in coronary sinus PO2 and coronary blood flow. Because of the pronounced vasoactive properties of the esters of adenosine-5'-carboxylic acid, a systematic study of the corresponding amides (14--50) was undertaken. In addition, several other analogues containing the N1-oxide function (51--52) or 2',3' substituents (3--9, 53--54) were studied.

The structures of seldomycin factors 1 and 2 have been determined by consideration of chemical degradation and spectral properties. Factor 1, also known as XK-88-1, is shown to be 6-O-(2-amino-2-deoxy-alpha-D-xylopyranosyl) paromamine (1) and factor 2, also known as XK-88-2, is shown to be 4'-deoxy-neamine (2). Mass spectral evidence has been obtained that suggests the most probable structure for seldomycin factor 3, also known as XK-88-3, is 6'-amino-6'-deoxyseldomycin factor 1 (12).

The biotransformation of lankamycin and congeners darcanolide and 11-acetyllankolide by a blocked mutant of the erythromycin-producing organism Streptomyces erythreus, which cannot synthesize erythromycin without supplementation with erythromycin precursors, was investigated. Darcanolide and 11-acetyllankolide were converted into the corresponding 15-deoxy-15-oxo derivatives. Lankamycin was transformed to 15-deoxy-15-oxolankamycin, 4"-deacetyl-l5-deoxy-15-oxolankamycin and 3'-de-O-methyllankamycin. None of the derivatives possessed high antimicrobial activity.

13C-NMR studies have confirmed the structures of (8S)-8-hydroxyerythromycins A- and B-6, 9;9, 11-acetal proposed by KROWICKI and ZAMOJSKI2, 3) for the products of the m-chloroperbenzoic acid oxidation of 8, 9-anhydroerythromycins A- and B-6, 9-hemiacetal. The preparations of (8S)-8-methylthiomethoxy- and (8S)-8-methoxyerythromycin B-6, 9;9, 11-acetals are described. The latter are stable in aqueous acetic acid under conditions which convert (8S)-8-hydroxyerythromycin B-6, 9;9, 11-acetalinto (8S)-8-hydroxyerythromycin B. In a paper describing the preparation of the C8-epimeric 8-hydroxyerythromycins B, we reported1) that buffered m-chloroperbenzoic acid oxidation of 8, 9-anhydroerythromycin B-6, 9-hemiacetal (1), followed by catalytic reduction of the resulting N-oxide to the free amine, gave (8S, 9S)-8, 9-anhydroerythromycin B-6, 9-hemiacetal-8, 9-epoxide (2). Our assignment of structure 2 was based on the expected course of olefin epoxidation with peracids and with apparently compatible spectral properties. In addition, the facile conversion of 2 to (8S)-8-hydroxyerythromycin B (3) in aqueous acetic acid was expected for the strained epoxy spiroacetal structure (2).

Several previously undescribed metabolites related to lankamycin have been isolated from fermentation broths of the lankamycin-producing organism Streptomyces violaceoniger. Two of these metabolites, of weak antibacterical activity, have been characterized as 15-O-(α-L-4-O-acetyl-arcanosyl)-lankamycin and 15-deoxy-15-oxo-lankamycin. The latter antibiotic is prepared in high yield by Jones oxidation of lankamycin.

The structure of XK-62-2 has been firmly established to be 6'-N-methylgentamicin C1a (3) by application of spectroscopic methods in conjunction with chemical degradation. The data obtained in every case are completely consistent with the proposed structure.

7-Epi-spectinomycin (9) and 7-epi-4(R)-dihydrospectinomycin (10) have been prepared and their structures firmly established by proton magnetic resonance. Both of these spectinomycin analogs are devoid of antibiotic activity.

The conversion of fortimicin E, a minor metabolite from the Micromonospora olivoasterospora fermentation which also produces fortimicin A and fortimicin B, to four 4-N-aminoacylfortimicins E was accomplished. The new 4-N-aminoacylfortimicins E showed only weak antimicrobial activity against several Gram-negative and Gram-positive microorganisms.